Profile
Sector:
HealthcareIndustry:
Diagnostics & ResearchCountry:
United StatesIPO:
15 July 2003Website:
http://www.adnas.comNext earnings report:
06 December 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Sat, 23 Nov 2024 00:22:39 GMTDividend
Analysts recommendations
Institutional Ownership
APDN Latest News
Is the next pandemic here. With health officials declaring Monkeypox a public health emergency, investors need to be watching Monkeypox-related stocks.
Applied DNA Sciences, Inc. (NASDAQ:APDN ) Q3 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Corporate Participants Sanjay Hurry - Head of IR Beth Jantzen - Chief Financial Officer Jim Hayward - Chairman, President and Chief Executive Officer Clay Shorrock - Chief Legal Officer and Head of Business Development Conference Call Participants Operator Good day, and welcome to the Applied DNA Fiscal Third Quarter 2024 Investor Conference Call. All participants will be listen-only mode.
Applied DNA Sciences (APDN) came out with quarterly earnings of $0.47 per share, beating the Zacks Consensus Estimate of a loss of $0.64 per share. This compares to loss of $4.80 per share a year ago.
Applied DNA Sciences (APDN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
STONY BROOK, NY / ACCESSWIRE / May 13, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA) and the Institute of Hematology and Blood Transfusion (ÚHKT/IHBT) have announced that an abstract on the development of an enzymatic, non-viral manufacturing workflow for efficient production of clinical-grade CAR T-cell therapies has been accepted for presentation at the European Hematology Association 2024 Hybrid Congress in Madrid, Spain from June 13 - 16, 2024. The accepted abstracts will be available on the Congress' website from May 14, 2024.
Here is how Applied DNA Sciences (APDN) and Encore Wire (WIRE) have performed compared to their sector so far this year.
Applied DNA Sciences, Inc. (APDN) Q1 2024 Earnings Call Transcript
Applied DNA Sciences (APDN) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to loss of $0.14 per share a year ago.
STONY BROOK, NY / ACCESSWIRE / February 5, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, today announced that it will release its first quarter fiscal 2024 financial results after market close on Thursday, February 8, 2024. In conjunction with this announcement, Applied DNA management will host a conference call for analysts and members of the investment community starting at 4:30 p.m.
Applied DNA Sciences, Inc. (NASDAQ:APDN ) Q4 2023 Earnings Conference Call December 7, 2023 4:30 PM ET Company Participants Sanjay Hurry - Head of IR Beth Jantzen - CFO James Hayward - Chairman, President and CEO Clay Shorrock - Chief Legal Officer and Head of Business Development Conference Call Participants Jason McCarthy - Maxim Group Yi Chen - H.C. Wainwright Operator Good Day and welcome to the Applied DNA Sciences Fiscal Fourth Quarter 2023 Financial Results Conference Call.
What type of business is Applied DNA Sciences?
Applied DNA Sciences, Inc., a biotechnology company, develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) in the Americas, Europe, Asia, and internationally. It operates through three segments: Therapeutic DNA Production Services; MDx Testing Services; and DNA Tagging and Security Products and Services. The Therapeutic DNA Production Services segment develops and commercializes the LinearDNA platform, which enables a cell-free manufacture of high-fidelity synthetic DNA sequences for use in nucleic acid-based therapeutics. The MDx Testing Services segment provides clinical molecular diagnostics (MDx) testing and clinical laboratory testing services; COVID-19 testing services, including test scheduling, sample collection, and automated results reporting for higher education institutions, private clients, and businesses under the safeCircle trademark; polymerase chain reaction (PCR) for production and detection of DNA and RNA; and MDx test kits and related supplies, as well as Isotopic analysis testing services. The DNA Tagging and Security Products and Services segment offers SigNature Molecular Tags, which provides a methodology to authenticate goods within large and complex supply chains for materials, such as cotton, nutraceuticals, and other products; SigNify portable DNA readers and SigNify consumable reagent test kits; and fiberTyping, which uses PCR-based DNA detection to detect a product's naturally occurring DNA sequences for the purposes of product provenance authentication and supply chain security. The company was formerly known as Datalink Systems, Inc. and changed its name to Applied DNA Sciences, Inc. in 2002. Applied DNA Sciences, Inc. was founded in 1983 and is headquartered in Stony Brook, New York.
What sector is Applied DNA Sciences in?
Applied DNA Sciences is in the Healthcare sector
What industry is Applied DNA Sciences in?
Applied DNA Sciences is in the Diagnostics & Research industry
What country is Applied DNA Sciences from?
Applied DNA Sciences is headquartered in United States
When did Applied DNA Sciences go public?
Applied DNA Sciences initial public offering (IPO) was on 15 July 2003
What is Applied DNA Sciences website?
https://www.adnas.com
Is Applied DNA Sciences in the S&P 500?
No, Applied DNA Sciences is not included in the S&P 500 index
Is Applied DNA Sciences in the NASDAQ 100?
No, Applied DNA Sciences is not included in the NASDAQ 100 index
Is Applied DNA Sciences in the Dow Jones?
No, Applied DNA Sciences is not included in the Dow Jones index
When was Applied DNA Sciences the previous earnings report?
No data
When does Applied DNA Sciences earnings report?
The next expected earnings date for Applied DNA Sciences is 06 December 2024